Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest and modulation of drug-induced apoptosis in human myeloid leukemia cells

Leukemia

Volumn 10, Issue 7, 1996, Pages 1150-1158

  Rao, A S ^a   Freemerman, A J ^a   Jarvis, W D ^a   Chelliah, J ^a   Bear, H D ^a   Mikkelsen, R ^a   Grant, S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Ara C; AS101; Bryostatin 1; Differentiation

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; BRYOSTATIN 1; CD11B ANTIGEN; CYCLIN DEPENDENT KINASE; CYTARABINE; ORGANOTELLURIUM DERIVATIVE; PROTEIN KINASE C ACTIVATOR; PROTEIN P21;

APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MYELOID LEUKEMIA; ONCOGENE C MYC; PRIORITY JOURNAL;

EID: 0030015621     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Pettit GR, Herald CL, Doubek DL, Herald DL, Arnold E, Clardy J. Isolation and structure of bryostatin 1. J Am Chem Soc 1982; 104: 6846-6848.
2. Steube KG, Drexler HG. Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin 1. Leuk Lymphoma 1993; 9: 141-148.
3. Kraft AS, Berkow RL. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun 1985; 131: 1109-1116.
4. Hennings H, Blumberg PM, Pettit GR, Herald CL, Shores R, Yuspa SH. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis 1987; 8: 8483-8487.
5. Kraft AS, Smith JB, Berkow RL. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci USA 1986; 83: 1334-1338.
6. II-protein kinase C to the nucleus of human promyelocytic leukemia (HL-60) cells. J Biol Chem 1991; 266: 28-33.
7. Stabel S, Parker PJ, Protein kinase C. Pharmacol Ther 1991; 51: 71-95.
8. Jones R, Sharkis S, Miller C, Rowinsky E, Burke P, May WS. Bryostatin 1, a unique biologic response modifier: antileukemic activity in vitro. Blood 1990; 75: 1319-1323.
9. Stone RM, Sariban E, Pettit GR, Kufe DW. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988; 72: 208-213.
10. Kraft AS, William F, Pettit GR, Lilly MB. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res 1989; 49: 1287-1293.
11. Grant S, McCrady C, Boise L, Westin EH, Pettit GR. Effects of bryostatin 1 on the metabolism and cytotoxicity of 1-β-P-D-arabinofuranosylcytosine in human leukemia cells. Biochem Pharm 1991; 42: 853-867.
12. May WS, Sharkis S, Esa A, Gebbia V, Kraft A, Pettit G, Sensenbrenner L. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci USA 1987; 84: 8483-8487.
13. Kennedy MJ, Prestigiacomo LJ, Tyler G, May WS, Davidson NE. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res 1992; 52: 1278-1283.
14. Dale IL, Bradshaw TD, Gescher A, Pettit GR. Comparison of the effects of bryostatins 1 and 2 and 12-O-tetradecanoylphorbol-13-acetate on protein kinase C activity in human lung carcinoma cells. Cancer Res 1989; 49: 3242-3245.
15. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Stern P, McDermott R, Potter M, Pettit GR. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993; 68: 418-424.
16. Grant S, Jarvis D, Swerdlow P, Turner A, Traylor R, Wallace H, Lin P-S, Pettit GR, Gewirtz DA. Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the macrocyclic lactone PKC activator bryostatin 1 is associated with enhanced fragmentation of mature DNA. Cancer Res 1992; 52: 6270-6278.
17. Jarvis WD, Gewirtz DA, Povirk L, Turner A, Traylor R, Pettit GR, Grant S. Effect of bryostatin 1 and other activators of protein kinase C on 1-β-D-arabinofuranosylcytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol 1994; 47: 839-852.
18. Jarvis WD, Povirk L, Turner A, Traylor R, Grant S. Induction of DNA fragmentation and cell death in (HL-60) human promyelocytic leukemia cells by pharmacologic inhibitors of protein kinase C. Cancer Res 1994; 54: 1707-1714.
19. Bertrand R, Solary E, O'Connor P, Kohn KW, Pommier Y. Induction of a common pathway of apoptosis by staurosporine. Exp Cell Res 1994; 211: 314-321.
20. Kalechman Y, Sotnik-Barkai I, Albeck M, Sredni B. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O′)tellurate (AS101). Cancer Res 1993; 53: 1838-1844.
21. Shani A, Tichler T, Catane R, Gurwith M, Rozenszajn LA, Levi E, Schlesinger M, Kalechman Y, Shalit F, Engelsrnan E, Farbstein H, Farbstein M, Albeck M, Sredni B. Immunologic effects of AS101 in the treatment of cancer patients. Nat Immun Cell Growth Reg 1990; 9: 182-190.
22. Sredni B, Kalechman Y, Albeck M, Gross O, Aurbach D, Sharon P, Sehgal SN, Gurwirth MJ, Michlin H. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin 1. Immunology 1990; 70: 473-477.
23. Kalechman Y, Albeck M, Sredni B. In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin. Cellular Immunol 1992; 143: 143-153.
24. Sredni B, Caspi RR, Klein A, Kalechman Y, Danziger Y, BenYa'akov M, Tamari T, Shalit F, Albeck M. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 1987; 330: 173-176.
25. Gallegher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzgar R, Aulakh C, Ting R, Ruscetti F, Gallo R. Characterization of the continuous differentiating cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979; 54: 713-733.
26. Jarvis DW, Kolesnick RW, Fornari FA, Traylor RS, Gerwirtz DA, Grant S. Activation of the sphingomyelinase pathway initiates apoptosis in a variety of mammalian cell lines. Proc Natl Acad Sci USA 1994; 91: 73-77.
27. Hass R, Bartels H, Topley N, Hadam M, Kohler L, Goppelt-Strube M. TPA-induced differentiation and adhesion of U937 cells: changes in ultrastructure, cytoskeletal organization and expression of cell surface antigens. Eur J Cell Biol 1989; 48: 282-293.
28. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
29. 2+ chelator, BAPTA/AM. Oncology Res 1995; 7: 381-392.
30. Rabinovitch PS, June CH, Grossmann A, Ledbetter J. Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J Immunol 1986; 137: 952-961.
31. Zhang W, Grasso L, McClain GD, Gambel AM, Cha Y, Travail S, Deisseroth AB, Mercer WE. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995; 55: 668-674.
32. Gowda SD, Koler RD, Bagby GJ. Regulation of c-myc expression during growth and differentiation of normal and leukemic myeloid progenitor cells. J Clin Invest 1986; 77: 271-278.
33. Sredni B, Kalechman Y, Shalit F, Albeck M. Synergism between AS101 and PMA in lymphokine production. Immunology 1990; 69: 110-116.
34. Szallasi Z, Smith CB, Pettit GR, Blumberg PM. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 12-acetate in NIH 3T3 fibroblasts. J Biol Chem 1994; 269: 2118-2124.
35. Grant S, Rao A, Freemerman AJ, Turner AJ, Kornstein MJ, Chelliah J, Jarvis WD. Divergent effects of calcium ionophore (A23187) on bryostatin 1-related differentiation and apoptosis in human promyelocytic leukemic cells (HL-60). Molec Cell Differ 1995; 3: 337-359.
36. Isakov N, Galron D, Mustelin T, Pettit GR, Altman A. Inhibition of phorbol ester-induced T cell proliferation by bryostatin 1 is associated with rapid degradation of protein kinase C. J Immunol 1993; 150: 1195-1204.
37. Aihira H, Asaoka Y, Yoshida K, Nishizuka Y. Sustained activation of protein kinase C is essential to HE-60 cell differentiation to macrophage. Proc Natl Acad Sci USA 1991; 88: 11062-11066.
38. Fibach E, Peled T, Rachmilewitz EA. Self-renewal and commitment to differentiation of human leukemic promyelocytic cells (HE-60). J Cell Physiol 1982; 113: 152-158.
39. 1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
40. Jiang H, Lin J, Su Z, Collart FR, Huberman E, Fisher PB. Induction of differentiation in human promyelocytic leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 1994; 9: 3397-3406.
41. 1 arrest involves pRB-related proteins and is disrupted by the human papilloma virus 16 E7 oncoprotein. Proc Natl Acad Sci USA 1994; 91: 5320-5324.
42. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915-1922.
43. Kraft AS, Baker VV, May WS. Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60). Oncogene 1987; 1: 111-118.
44. Asiedu C, Biggs J, Lilly M, Kraft AS. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res 1995; 55: 3716-3720.
45. 1. Mol Cell Biol 1988; 8: 1614-1624.
46. Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990; 79: 448-453.
47. 1 arrest. J Clin Invest 1992; 89: 854-860.
48. Solary E, Bertrand R, Kohn K, Pommier Y. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 1993; 81: 1359-1368.
49. Del Bino G, Li F, Traganos F, Darzynkiewicz Z. Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs. Leukemia 1994; 8: 281-288.